Cotempla XR-ODT Approval History
FDA Approved: Yes (First approved June 19, 2017)
Brand name: Cotempla XR-ODT
Generic name: methylphenidate
Dosage form: Extended-Release Orally Disintegrating Tablets
Company: Neos Therapeutics, Inc.
Treatment for: ADHD
Cotempla XR-ODT (methylphenidate) is a once-daily, extended-release, orally disintegrating tablet formulation of the central nervous system (CNS) stimulant methylphenidate indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.
Development History and FDA Approval Process for Cotempla XR-ODT
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.